Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1

Vaccine

Volumn 18, Issue 17, 2000, Pages 1793-1801

  O'Hagan, D T ^a   Ugozzoli, M ^a   Barackman, J ^a   Singh, M ^a   Kazzaz, J ^a   Higgins, K ^a   Vancott, T C ^b   Ott, G ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM 51; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; ISCOM; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY; POLYGLACTIN; PROTEIN P120; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BABOON; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; EMULSION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIBODY SPECIFICITY; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; MICROSPHERES; PAPIO; POLYSORBATES; RECOMBINANT PROTEINS; SQUALENE; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC;

EID: 0033997105     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00522-8     Document Type: Article

References (41)

1. Global overview: a powerful HIV/AIDS pandemic. AIDS in the world. Mann J., Tarantola D. Status and Trends of the HIV/AIDS Pandemic. 1996;Oxford University Press, New York.
2. Dolin R. Human studies in the development of human immunodeficiency virus vaccines. J. Infect. Dis. 172:1995;1175-1183.
3. SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis. 170:1994;1288-1291.
4. Mascola J.R., Snyder S.W., Weislow O.S., Belay S., Belshe R., Schwartz D., Clements M., Dolin R., Graham B., Gorse G., Keefer M., McElrath M., Walker M., Wagner K., McNeil J., McCutchan F., Burke D. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:1996;340-348.
5. Igarashi T., Brown C., Azadegan A., Haigwood N., Dimitrov D., Martin M.A., Shibata R. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat. Med. 5:1999;211-216.
6. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M.W., Martin M.A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:1999;204-210.
7. Mascola Jr, Lewis M.L., Stiegler G., Haris D., Vancott T.C., Hayes D., Louder M.K., Brown C.R., Sapan C.V., Frankel S.S., Lu Y., Robb M.L., Katinger H., Birx D.L. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:1999;4009-4018.
8. Rowland-Jones S.L., Nixon D.F., Aldhous M.C., Gotch F., Ariyoshi K., Hallam N., Kroll J.S., Froebel K., McMichael A. HIV-specific cytotoxic T cell activity in an HIV exposed but uninfected infant. Lancet. 341:1993;860-861.
9. Beyrer C., Artenstein A.W., Rugpao S., Stephens H., Vancott T.C., Rob M.L., Rinkaew M., Birx D.L., Khamboonruang C., Zimmerman P.A., Nelson K.E., Natpratan C. Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. J. Infect. Dis. 179:1999;59-67.
10. Clerici M., Giorgi J.V., Chou C.-C., Gudeman V.K., Zack J.A., Gupta P., Ho H.-N., Nishanian P.G., Berzofsky J.A., Shearer G.M. Cell-mediated immune response to human immunodeficiency virus (HIV-1) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J. Infect. Dis. 165:1992;1012-1019.
11. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., Farthing C., Ho D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
12. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:1994;6103-6110.
13. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., Segal J.P., Cao Y., Rowland-Jones S.L., Cerundolo V., Hurley A., Markowitz M., Ho D.D., Nixon D.F., McMichael A.J. Quantitation of HIV-1 specific cytotoxic lymphocytes and plasma load of viral RNA. Science. 279:1998;2103-2106.
14. + T cell responses associated with control of viremia. Science. 278:1997;1447-1450.
15. Mazzoli S., Trabattoni D., Lo Caputo S., Piconi S., Ble C., Meacci F., Ruzzante S., Salvi A., Semplici F., Longhi R., Fusi M.L., Tofani N., Biasin M., Villa M.L., Mazzotta F., Clerici M. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat. Med. 3:1997;1250-1257.
16. + nef-specific cytotoxic T cells in vaccinated macaques. Nat. Med. 1:1995;1167-1173.
17. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 234:1986;1563-1566.
18. + T cells. Science. 270:1995;1811-1815.
19. Eldridge J.H., Staas J.K., Meulbroek J.A., Tice T.R., Gilley R.M. Biodegradable and biocompatible poly (DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 59:1991;2978-2986.
20. O'Hagan D.T., Rahman D., McGee J.P., Jeffery H., Davies M.C., Williams P., Davis S.S., Challacombe S.J. Biodegradable microparticles as controlled release antigen delivery systems. Immunol. 73:1991;239-242.
21. Vordermeir H.M., Coombes A.G.A., Jenkins P., McGee J.P., O'Hagan D.T., Davis S.S., Singh M. Synthetic delivery systems for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable microparticles. Vaccine. 13:1995;1576-1582.
22. Cleland J.L., Lim A., Barron L., Duenas E.T., Powell M.F. Development of a single-shot subunit vaccine for HIV-1: Part 4. Optimizing microencapsulation and pulsatile release of MN rgp120 from biodegradable microspheres. J. Cont. Rel. 47:1997;135-150.
23. Cleland Jl, Lim A., Daugherty A., Barron L., Desjardin N., Duenas E.T., Eastman D.J., Vennari J.C., Wrin T., Beman P., Murthy K.K., Powell M.F. Development of a single-shot subunit vaccine for HIV-1: Part 5. Programmable in vivo autoboost and long lasting neutralizing response. J. Pharm. Sci. 87:1998;1489-1495.
24. O'Hagan D.T., McGee J.P., Boyle R., Gumaer D., Li X.-M., Potts B., Wang C.Y., Koff W.C. The preparation, characterization and pre-clinical evaluation of an orally administered HIV-1 vaccine, consisting of a branched synthetic peptide immunogen entrapped in controlled release microparticles. J. Cont. Rel. 36:1995;75-84.
25. + Th1 cells. Vaccine. 113:1995;1741-1749.
26. Jeffery H., Davis S.S., O'Hagan D.T. The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm. Res. 10:1993;362-368.
27. McGee J.P., Singh M., Li X.M., Qiu H., O'Hagan D.T. The encapsulation of a model protein in poly (D, L-lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility. J. Microencap. 14:1997;197-210.
28. O'Hagan D.T., Jeffery H., Davis S.S. The preparation and characterization of poly(lactide-co-glycolide) microparticles. III: Microparticle/polymer degradation rates and the in vitro release of a model protein. Int. J. Pharm. 103:1994;37-45.
29. Barackman J.D., Singh M., Ugozzoli M., Ott G.S., O'Hagan D.T. Oral immunization with poly(lactide-co-glycolide) microparticles containing an entrapped recombinant glycoprotein (gd2) from herpes simplex type 2 virus. STP Pharma. Sci. 8:1998;41-46.
30. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., Hoogevest P.V., Van Nest G. Design and evaluation of a safe and potent adjuvant for human vaccines. Newman J.M., Powell M.F. Vaccine Design: The Subunit and Adjuvant Approach. 1995;277-295 Plenum Press, New York.
31. Wilson AD, Lovgren-Bengtsson K, Villacres-Ericsson M, Morein B, Morgan AJ. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines, Vaccine 1999;17:1282-1290.
32. Vancott T.C., Mascola J.R., Kaminski R.W., Kalyanaraman V., Hallberg P.L., Burnett P.R., Ulrich J.T., Rechtman D.J., Birx D.L. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71:1997;4319-4330.
33. Mascola J., Weislow O., Snyder S., Belay S., Yeager M., McCutchan F., McNeil J., Burke D., Walker M.C. Neutralizing antibody activity in sera from human immunodeficiency virus type-1 vaccine recipients form the AIDS vaccine clinical trials network. AIDS Res. Hum. Retroviruses. 10:1994;S55.
34. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., Clements M.L., Dolin R., Graham B.S., Gorse G.J., Keefer M.C., McElrath M.J., Walker M.C., Wagner K.F., McNeil J.G., McCutchan F.E., Burke D.S. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccines Evaluation Group. J. Infect. Dis. 173:1996;340-348.
35. Vancott T.C., Polonis V.R., Loomis L.D., Michael N.L., Nara P.L., Birx D.L. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retroviruses. 11:1995;1379-1391.
36. Doe B., Steimer K.S., Walker C.M. Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans. Euro. J. Immunol. 24:1994;2369-2376.
37. O'Hagan D.T., Jeffery H., Davis S.S. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine. 11:1993;965-969.
38. Maloy K.J., Donachie D.T., O'Hagan D.T., Mowat M.A. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunol. 81:1994;661-667.
39. Harris S.J., Woodrow S.A., Gearing A.J.H., Adams S.E., Kingsman A.J., Layton G.T. The effects of adjuvants on CLT induction by V3: Ty-virus-like particles (V3-VLPs) in mice. Vaccine. 14:1996;971-976.
40. O'Hagan D.T., Singh M., Gupta R.K. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv. Drug Del. Rev. 32:1998;225-246.
41. LaCasse R.A., Follis K.E., Trahey M., Scarborough J.D., Littman D.R., Nunberg J.H. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science. 283:1999;357-362.